Loading...
UCB SA
UCBJF•PNK
Healthcare
Biotechnology
$210.15
$-3.90(-1.82%)
UCB SA (UCBJF) Financial Performance & Statements
Review UCB SA’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
17.14%
↑ 17.14%
Operating Income Growth
119.21%
↑ 119.21%
Net Income Growth
210.50%
↑ 210.50%
Operating Cash Flow Growth
63.21%
↑ 63.21%
Operating Margin
9.15%
↑ 9.15%
Gross Margin
65.90%
↑ 65.90%
Net Profit Margin
4.40%
↑ 4.40%
ROE
2.53%
↑ 2.53%
ROIC
3.61%
↑ 3.61%
UCB SA (UCBJF) Financial Statements
Explore quarterly and annual reports for UCB SA stock.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $2.79B | $2.66B | $1.33B | $2.59B |
| Cost of Revenue | $851.00M | $1.009B | $452.50M | $901.00M |
| Gross Profit | $1.94B | $1.65B | $879.00M | $1.69B |
| Gross Profit Ratio | $0.70 | $0.62 | $0.66 | $0.65 |
| R&D Expenses | $789.00M | $871.00M | $435.50M | $759.00M |
| SG&A Expenses | $1.07B | $863.00M | $483.50M | $758.00M |
| Operating Expenses | $1.62B | $1.48B | $826.00M | $1.21B |
| Total Costs & Expenses | $2.47B | $2.49B | $1.28B | $2.11B |
| Interest Income | $15.00M | $31.00M | $33.00M | $16.00M |
| Interest Expense | $92.00M | $115.00M | $0.00 | $95.00M |
| Depreciation & Amortization | $318.00M | $376.00M | $188.00M | $315.00M |
| EBITDA | $644.00M | $552.00M | $270.50M | $794.00M |
| EBITDA Ratio | $0.23 | $0.21 | $0.20 | $0.31 |
| Operating Income | $323.00M | $176.00M | $82.50M | $479.00M |
| Operating Income Ratio | $0.12 | $0.07 | $0.06 | $0.19 |
| Other Income/Expenses (Net) | -$77.00M | -$156.00M | -$62.50M | -$278.50M |
| Income Before Tax | $246.00M | $40.00M | $20.00M | $401.00M |
| Income Before Tax Ratio | $0.09 | $0.02 | $0.02 | $0.15 |
| Income Tax Expense | $38.00M | $8.00M | $4.00M | $90.00M |
| Net Income | $208.00M | $32.00M | $16.00M | $311.00M |
| Net Income Ratio | $0.07 | $0.01 | $0.01 | $0.12 |
| EPS | $1.10 | $0.17 | $0.08 | $1.64 |
| Diluted EPS | $1.07 | $0.16 | $0.08 | $1.60 |
| Weighted Avg Shares Outstanding | $189.89M | $189.78M | $195.99M | $189.26M |
| Weighted Avg Shares Outstanding (Diluted) | $195.007M | $199.62M | $195.63M | $194.75M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan